Number of ongoing Clinical Trials (for drugs) involving Glaucoma by Phase

  • There are currently 138 ongoing clinical trials involving Glaucoma

  • Of the 138 trials,58 trials are in Phase II

  • Furthermore, 33 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Glaucoma by Phase

Published: Oct 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Glaucoma, an ophthalmology indication. The highest number of ongoing clinical trials involving Glaucoma is in the Asia-Pacific region. Europe and North America are among some of the other prominent regions involved in Glaucoma-related drug trials.

Santen Pharmaceutical Co Ltd: The leading ongoing Glaucoma related clinical trials sponsor

Santen Pharmaceutical Co Ltd, the Japan-based pharmaceutical and healthcare company, is the top sponsor for Glaucoma-related ongoing clinical trials.

Allergan Ltd, Sun Yat-sen University, Kowa Co Ltd, and Intratus Incare a few other notable sponsors involving Glaucoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Glaucoma

Aflibercept (Eylea), Bimatoprost (Lumigan/Lumivis/Lumopta), Brimonidine tartrate (Alphagan, Alphagan P, Enidin P), and Dorzolamide hydrochloride and timolol maleate (Cosopt, Cosopt Mini, Dormolol, Cosopt PF) are among the key marketeddrugs involving Glaucoma.     

Aflibercept (Eylea), a Placenta Growth Factor Inhibitor, and Vascular Endothelial Growth Factor AInhibitor drug, is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Eylea is indicated for the treatment of Glaucoma and several other indications including Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema, Myopia, Diabetic Macular Edema, Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy (NPDR), Wet (Neovascular / Exudative) Macular Degeneration. The drug is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Regeneron Pharmaceuticals Inc, and Bayer AG. Aflibercept was first approved in 2011 and is formulated as an iso-osmotic injection solution for intravitreal route of administration.

Bimatoprost (Lumigan/Lumivis/Lumopta), a Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR) Agonist drug, is a synthetic prostaglandin analog, acts as a potent ocular hypotensive agent. Bimatoprost is indicated for reducing the elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Lumigan is marketed globally including the US, the UK, Australia, France, Germany, and Japan by several prominent pharma giants including AbbVie IncAllergan Ltd, and Shionogi & Co Ltd. Lumigan was first approved in 2001 and is formulated as drops, solution for ophthalmic route of administration.

Looking to discover more data & insights?

Sign up for a free account to monitor sector landscapes, pinpoint market trends & more.

Single License £500 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions

Related Data & Insights

Related Companies

McKesson Corp

United States of America

Johnson & Johnson

United States of America

Pfizer Inc

United States of America

AbbVie Inc

United States of America

Novartis AG

Switzerland

Bayer AG

Germany

Merck & Co Inc

United States of America

GlaxoSmithKline Plc

United Kingdom

Bristol-Myers Squibb Co

United States of America

Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer